

# Variance of Consolidated Results Between the Year Ended 31 December 2025 and the Previous Year

**Tokyo, Japan and Cambridge, UK, 13 February 2026** – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) addresses the variance between the consolidated financial results for the fiscal year ended December 2025 (the “current term consolidated results”) and the consolidated financial results for the fiscal year ended December 2024 (the “previous term consolidated results”) as the Company did not disclose consolidated results forecasts for the year ended 31 December 2025.

## 1. The variance between Current Term Consolidated Results and Previous Term Consolidated Results

	Revenue	Operating profit (loss)	Profit (loss) before tax	Net profit (loss) attributable to owners of the parent company
Previous term consolidated results (A) (Million yen)	28,835	-5,423	-4,662	-4,838
Current term consolidated results (B) (Million yen)	29,615	-8,462	-14,950	-12,530
Change (B-A) (Million yen)	780	-3,039	-10,288	-7,692
Percentage change (%)	2.7%	—	—	—

## 2. Reasons for the variance

Revenue increased by JPY 780 million year on year to JPY 29,615 million. This increase reflects higher revenue from commercialized products, with PIVLAZ® increasing 6.8% compared with the previous consolidated fiscal year to JPY 13,511 million and QUVIVIQ® increasing 223.9% to JPY 4,327 million. In contrast, milestone income decreased by JPY 3,278 million compared with the previous consolidated fiscal year in value, although the number of milestones achieved increased to seven in the fiscal year under review from five in the previous consolidated fiscal year.

Selling, general and administrative expenses decreased by JPY 790 million year on year as a result of the Company’s cost reduction initiatives. However, research and development (“R&D”) expenses increased by JPY 2,650 million year on year due to increased R&D investment in the clinical-stage pipeline and in the obesity and metabolic disease area, as well as the impact of yen depreciation. As a result, operating loss was JPY 8,462 million. In finance costs for the fiscal year under review, the Company recorded expenses associated with amendments to the terms of its corporate bonds and a loss on remeasurement of contingent consideration following the positive progress of certain R&D programs in an acquired business. This resulted in a loss before income taxes of JPY 14,950 million. Loss for the year attributable to owners of the parent company was JPY 12,530 million, which includes a tax benefit relating to deferred tax.

–END–

## **About Nxera Pharma**

Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit [www.nxera.life](http://www.nxera.life)

LinkedIn: [@NxeraPharma](#) | X: [@NxeraPharma](#) | YouTube: [@NxeraPharma](#)

*QUVIVIQ™ is trademark of Idorsia Ltd.*

## **Enquiries:**

### **Nxera – Media and Investor Relations**

Shinya Tsuzuki, VP, Head of Investor Relations

Maya Bennison, Communications Manager

+81 (0)3 5210 3399 | +44 (0)1223 949390 | [IR@Nxera.life](mailto:IR@Nxera.life)

### **MEDiSTRAVA (for International Media)**

Mark Swallow, Frazer Hall, Erica Hollingsworth

+44 (0)203 928 6900 | [Nxera@medistrava.com](mailto:Nxera@medistrava.com)

## **Forward-looking statements**

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.